[Intradermal reaction with Paracoccidoides brasiliensis polysaccharide in South American blastomycosis].

C. F. Netto,A. Raphael

1961-07-01

Revista do Instituto de Medicina Tropical de São Paulo

Abstract:

What problem does this paper attempt to address?

A node-disjoint multi-path extension of the location prediction based routing protocol for mobile ad hoc networks

N. Meghanathan

DOI: https://doi.org/10.1109/ICSPCS.2009.5306406

2009-10-30

Abstract:We propose a node-disjoint multi-path extension to the location prediction-based routing protocol (LPBR-M) to reduce the number of broadcast multi-path route discoveries for mobile ad hoc networks. During a broadcast route discovery, the intermediate forwarding nodes include their location and mobility information in the Route-Request messages. Upon failure of all the node-disjoint paths learnt from the latest route discovery, the destination runs the algorithm to determine the set of node-disjoint paths on a predicted global topology, constructed from the location and mobility information collected during the latest broadcast route discovery, and sends a sequence of Route-Reply messages on each of the predicted paths. If the source receives at least one Route-Reply message within certain time, it continues to send the data packets along the newly learnt node-disjoint paths. Otherwise, the source initiates another broadcast route discovery. Simulation results of LPBR-M along with the link-disjoint path based AOMDV and node-disjoint path based AODVM routing protocols indicate that LPBR-M incurs the longest time between successive broadcast route discoveries and a hop count close to that incurred by the minimum hop count based multi-path protocols.
CHILD syndrome in 3 generations: the importance of mild or minimal skin lesions.

M. Bittar,R. Happle,K. Grzeschik,L. Leveleki,M. Hertl,D. Bornholdt,A. König

DOI: https://doi.org/10.1001/ARCHDERM.142.3.348

2006-03-01

Archives of Dermatology

Abstract:BACKGROUND CHILD syndrome (congenital hemidysplasia with ichthyosiform nevus and limb defects, Online Mendelian Inheritance in Man 308050) is an X-linked dominant trait with lethality for male embryos. The disorder is caused by mutations in NSDHL (Online Mendelian Inheritance in Man 300275), a gene playing an important role in the cholesterol biosynthetic pathway. Most reports deal with sporadic cases, and only 5 cases of mother-to-daughter transmission have been documented. We present here a family with mild features of CHILD syndrome in 3 generations. Molecular analysis was used to confirm the diagnosis. OBSERVATIONS We studied 14 members of a family with CHILD syndrome. The 23-year-old proposita, her mother, 2 aunts, and her grandmother presented with mild or minimal skin lesions that had been present since infancy. Analysis of the NSDHL gene showed missense mutation c.370G-->A in these 5 patients. This mutation was absent in the 9 clinically unaffected family members tested. CONCLUSIONS In this family, we recognized CHILD syndrome with mild or minimal features in 3 generations because we were able to verify our clinical diagnosis by means of molecular analysis. We assume that many cases that so far have been considered sporadic may in fact be familial when a meticulous physical examination of female family members is combined with molecular testing.
Transesophageal echocardiography guidance for percutaneous closure of PFO and a new method to improve the diagnosis and safety during the procedures

Limin Luo,Zehan Xie,Qiaoyan Wu,Qiang Liu,Huiping Hou,Yongshi Wang,Xianhong Shu

DOI: https://doi.org/10.3389/fcvm.2024.1428380

2024-07-31

Abstract:Purpose: Percutaneous patent foramen ovale (PFO) closure is becoming more and more common for the treatment or prevention of PFO-associated right-to-left shunt (RLS). This study aims to investigate the value of transesophageal echocardiography (TEE) in percutaneous PFO closure, and to explore a new method that can improve intraoperative diagnosis and surgical safety. Materials and methods: Based on our inclusion and exclusion criteria, we enrolled 73 patients between 16 and 70 years old (average age 43.25 ± 14.87 years) who underwent percutaneous PFO closure at the Department of Cardiac Surgery, Zhongshan Hospital (Xiamen), Fudan University, from January 2022 to December 2023. Out of the 73 enrolled patients, there were 28 males (38.36%) and 45 females (61.64%), 29 migraine patients (39.73%), 14 patients (19.19%) with headache and dizziness, 14 patients (19.18%) with a history of cerebral infarction (CI), and 25 patients (34.25%) with CI, lacunar infarction or ischemic focus on magnetic resonance imaging (MRI). All patients received routine transthoracic echocardiography (TTE) and agitated saline contrast echocardiography (ASCE) before operations. Percutaneous closure of PFO was completed under the guidance of TEE. In 12 patients, the method of "injection of heparinized sterile saline through the delivery sheath" was used to observe their RLS, and the anatomical characteristics of the PFO according to the shunt path were monitored and evaluated. This method was also applied to some patients to guide the conveyor to pass through the foramen ovale (FO) channel safely and effectively, thereby improving the success rate of PFO closure. Results: The application of TEE during the procedure of percutaneous PFO closure, including preoperative evaluation, intraoperative guidance, and postoperative reevaluation, can offer further details about the anatomical and shunt characteristics of PFO, improve the diagnosis rate, and confirm the safety of the surgical path. It ensures the safety and reliability of the whole operation, greatly improving the success rate and reducing postoperative complications. Conclusions: TEE guidance of percutaneous PFO closure has the advantages of minimal trauma, no radiation and real-time visualization, while injecting heparinized sterile saline through the delivery sheath is safer and more effective in improving the success rate and reducing postoperative complications.
Patent Foramen Ovale Closure for Nonstroke Indications

Akilesh P Honasoge,Hussam S Suradi,Jonathan M Tobis,Clifford J Kavinsky

DOI: https://doi.org/10.1016/j.jscai.2023.101135

2023-09-16

Abstract:The patent foramen ovale (PFO) is a flap or tunnel-like communication in the atrial septum present in 20% to 34% of the adult population. In most cases, it is a benign finding and poses no health risk. However, some PFOs may provide a conduit for bloodborne materials, such as thrombi, vasoactive substances, or air to pass into the systemic circulation causing a paradoxical embolus. PFOs have been linked with several clinical disease states including cryptogenic stroke, migraine headache, platypnea-orthodeoxia, and decompression illness. Percutaneous PFO closure provides a practical solution to the problem of PFO in carefully selected populations. Recent randomized control trials have demonstrated that PFO closure in patients with cryptogenic stroke is associated with reduced rates of recurrent stroke compared with medical therapy. This translated into a dramatic increase in the number of PFO closure procedures worldwide, primarily for the indication of cryptogenic stroke, with high procedural success and low complication rates. However, there are no randomized clinical trials available to support PFO closure in other clinical conditions. This article reviews potential indications, existing data, and management approaches for PFO closure in disorders other than cryptogenic stroke.
Current status of transcatheter closure of patent foramen ovale

Igor F. Palacios

DOI: https://doi.org/10.47307/gmc.2020.128.3.8

2020-08-10

Gaceta Médica de Caracas

Abstract:A patent foramen ovale (PFO) is a highly prevalent structure among the adult population. It allows the shunt of blood through the inter-atrial septum and has been associated with cryptogenic stroke, transient ischemic attack, significant right to left shunting resulting in resting and exercise-induced hypoxemia, platypnea orthodeoxia syndrome, and decompression sickness after scuba diving and migraines. Currently, transthoracic and transesophageal echocardiography and transcranial Doppler are the most important diagnostic tools, for the diagnosis of PFO. The sensitivity and specificity of the study depend on the modalities available: transthoracic (TTE), transesophageal (TEE), and transcranial Doppler (TCD), as well as the intravenous use of agitated saline and the site of injection.
Urinary bladder prostanoids--their synthesis, function and possible role in the pathogenesis and treatment of disease.

D. Mikhailidis,J. Jeremy,P. Dandona

DOI: https://doi.org/10.1016/S0022-5347(17)44109-7

1987-03-01

Abstract:
Patent Foramen Ovale Closure in Special Clinical Situations: More Questions Than Answers?

Anastasios Apostolos,Polyxeni Alexiou,Amalia Papanikolaou,Georgios Trantalis,Maria Drakopoulou,Nikolaos Ktenopoulos,Ioannis Kachrimanidis,Panayotis K. Vlachakis,Ismini Tsakiri,Grigorios Chrysostomidis,Konstantina Aggeli,Costas Tsioufis,Konstantinos Toutouzas

DOI: https://doi.org/10.3390/life14060706

2024-05-30

Life

Abstract:Patent foramen ovale (PFO) is a remnant of the foetal circulation resulting from incomplete occlusion of the septum primum and septum secundum. Although prevalent in about 25% of the population, it mainly remains asymptomatic. However, its clinical significance in situations such as cryptogenic stroke, migraine, and decompression illness (DCI) has been well described. Recent randomised clinical trials (RCTs) have demonstrated the efficacy of percutaneous PFO closure over pharmacological therapy alone for secondary stroke prevention in carefully selected patients. Notably, these trials have excluded older patients or those with concurrent thrombophilia. Furthermore, the role of closure in other clinical conditions associated with PFO, like decompression sickness (DCS) and migraines, remains under investigation. Our review aims to summarise the existing literature regarding epidemiology, pathophysiological mechanisms, optimal management, and closure indications for these special patient groups.

biology
Transcatheter PFO closure for cryptogenic stroke: current approaches and future considerations

Moemen Eltelbany,Raghav Gattani,Araba Ofosu-Somuah,Abdulla Damluji,Kelly C. Epps,Wayne B. Batchelor

DOI: https://doi.org/10.3389/fcvm.2024.1391886

IF: 3.6

2024-05-21

Frontiers in Cardiovascular Medicine

Abstract:Patent Foramen Ovale (PFO) is a common congenital atrial septal defect present in 20%–35% of the general population. Although generally considered a benign anatomic variant, a PFO may facilitate passage of a thrombus from the venous to arterial circulation, thereby resulting in cryptogenic stroke or systemic embolization. A PFO is detected in nearly one half of patients presenting with cryptogenic stroke and often considered the most likely etiology when other causes have been excluded. In this review, we discuss the contemporary role of transcatheter closure of PFO in the treatment of cryptogenic stroke, including devices currently available for commercial use in the United States (Amplatzer PFO TM Occluder and Gore TM Cardioform Septal Occluder) and a novel suture-mediated device (NobleStitch TM EL) under clinical investigation. To provide the best care for cryptogenic stroke patients, practitioners should be familiar with the indications for PFO closure and corresponding treatment options. Graphical . PFO closure devices: past present and future. © Devon Medical Art LLC.

cardiac & cardiovascular systems
Transcatheter closure of patent foramen ovale with radiofrequency: Acute and intermediate term results in 144 patients

Horst Sievert,Peter Ruygrok,Matt Salkeld,Helmut Baumgartner,Bernhard Meier,Stephan Windecker,Jean‐Michel Juliard,Pierre Aubry,Christiane Tiefenbacher,Ulrike Krumsdorf,Paul Vermeersch,Peter Ewert,Jean François Piéchaud,Jean-Michel Juliard

DOI: https://doi.org/10.1002/ccd.21809

IF: 2.3

2009-01-01

Catheterization and Cardiovascular Interventions

Abstract:AIMS: Currently available devices for transcatheter closure of patent foramen ovale (PFO) which rely on a permanent implant have limitations, including late complications. The study objective was to evaluate the safety, feasibility, and effectiveness of the PFx Closure System, the first transcatheter technique for PFO closure without an implantable device.METHODS AND RESULTS: A prospective study of 144 patients was conducted at nine clinical sites from October 2005 through August 2007. All patients had a history of cryptogenic stroke, transient ischemic attack, migraines, or decompression illness. The mean balloon stretched diameter of the PFO was 7.9 +/- 2.5 mm. Technical success (successful application of radiofrequency energy) was achieved in 130 patients. One patient required a transfusion as a result of blood loss during the procedure. There were no other major procedural complications. There were no recurrent strokes, deaths, conduction abnormalities, or perforations following the procedure. At a mean follow-up of 6 months, successful closure was achieved in 79 patients (55%). In PFOs with balloon sized or stretched diameters less than 8 mm, the closure rate was 72% (53/74).CONCLUSION: This study demonstrates that transcatheter closure of a PFO without a permanent implant is technically feasible and safe. Further technique and device modifications are required to achieve higher closure rates.

cardiac & cardiovascular systems
Clinical efficacy of solo transcatheter closure of patent foramen ovale guided by transthoracic echocar-diography

Wenjun Zhou,Jin Lin,Xinpeng Jiang,Hang Yang,Yichen Gong,Yuanhao Fu,Qingli Sun,Yu Fu,Xiaogang Li,Jieli Feng,Xinhang Feng,Xiaoming Li,Zhe Zhang

DOI: https://doi.org/10.11817/j.issn.1673-9248.2020.02.008

2020-01-01

Abstract:Objective:To observe the safety and efficacy of solo transcatheter closure of Patent Foramen Ovale (PFO) guided solely by transthoracic echocardiography (TTE).Methods:A total of 25 cases were retrospectively included who underwent the solo transcatheter closure of PFO guided by TTE in Peking University Third Hospital from December 2018 to December 2019. They were 20 females and 5 males with average age of (42.3±7.8) years. TTE was performed immediately after percutaneous closure. The follow-up interviews were conducted at 1 month, 3 months, and 6 months after the procedure, respectively. There were 6 patients with cryptogenic stroke (RoPE score＞6) and 19 patients with obstinate migraine. The presence of PFO was confirmed by preoperative transesophageal echocardiography (TEE). The diameter of PFO was 2-3 mm and the diameter of tunnel was 4-8 mm. The contrast-enhanced transcranial doppler (cTCD) was 2-3 grade.Results:All patients were successfully treated with the solo transcatheter closure of PFO guided by TTE. The mean procedural time (from puncture to sheath removal) was (32.1±7.5) mins. During the operation, 3 cases presented vagal reflex and 2 cases developed transient ventricular arrhythmia, which disappeared after conservative treatment. All patients were discharged the next day after operation without complications, e.g. pericardial effusion, peripheral vascular injury, or cardiac perforation. During the follow-ups, no patients suffered from pericardial effusion, occluder malposition, residual shunt, recurrence of headache and stroke. The cTCD is normal.Conclusion:The solo transcatheter closure of PFO guided by TTE is an effective procedure with high successful rate and low rate of complications.
Comparison of three echo-guidance techniques in percutaneous patent foramen ovale closure for stroke prevention: Conventional transoesophageal, microprobe transoesophageal and intracardiac echocardiography

Iphigénie Reibel,Marie Hauguel-Moreau,Paul Guedeney,Georges Hage,Nadjib Hammoudi,Guillaume Duthoit,Michel Zeitouni,Benoit Lattuca,Mathieu Kernéis,Jean-Philippe Collet,Johanne Silvain,Gilles Montalescot,ACTION Study Group

DOI: https://doi.org/10.1016/j.acvd.2023.08.006

Abstract:Background: Recent randomized trials have demonstrated a consistent reduction in recurrent stroke after percutaneous transcatheter patent foramen ovale closure versus medical therapy in patients with recent cryptogenic stroke. Aim: To compare the safety and efficacy of intracardiac echocardiography-guided and microprobe transoesophageal echocardiography-guided patent foramen ovale closure under local anaesthesia with transoesophageal echocardiography-guided patent foramen ovale closure under general anaesthesia. Methods: This prospective observational single-centre study included 194 consecutive patients scheduled for patent foramen ovale closure for secondary prevention of stroke from February 2018 to December 2019. Patients were asked to choose between an intracardiac echocardiography-guided, microprobe transoesophageal echocardiography-guided or transoesophageal echocardiography-guided procedure. The primary endpoint was the rate of successful closure at 6 months, defined as correct positioning of the device without severe shunt on 6-month contrast echocardiography. Results: Successful closure was high and did not differ between groups: 97.8% (95% confidence interval 88.5-99.9%) in the intracardiac echocardiography-guided group versus 96.9% (95% confidence interval 83.8-99.9%) in the microprobe transoesophageal echocardiography-guided group and 99.1% (95% confidence interval 95.3-99.9%) in the transoesophageal echocardiography-guided group (P=0.63). Adverse events related to patent foramen ovale closure were low and did not differ between groups. Conclusion: Our preliminary real-world experience suggests good efficacy and safety with intracardiac echocardiography and microprobe transoesophageal echocardiography guidance compared with conventional transoesophageal echocardiography guidance for percutaneous transcatheter patent foramen ovale closure in recurrent stroke prevention.
A Prospective, Single-Center, Phase I Clinical Trial to Evaluate the Value of Transesophageal Echocardiography in the Closure of Patent Foramen Ovale With a Novel Biodegradable Occluder

Yajuan Du,Hang Xie,Hui Shao,Gesheng Cheng,Xingye Wang,Xumei He,Beidi Lan,Lu He,Yushun Zhang

DOI: https://doi.org/10.3389/fcvm.2022.849459

IF: 3.6

2022-05-04

Frontiers in Cardiovascular Medicine

Abstract:Objective: Traditional metal alloy occluders for the closure of patent foramen ovale (PFO) may be associated with some potential complications, and may restrict the trans-septal access to the left atrium for future treatment of left-sided heart disease. Increasing attention has been paid to novel biodegradable occluders (NBOs) to achieve PFO closure. We aimed to evaluate the role of transesophageal echocardiography (TEE) in the diagnostic and anatomical evaluation of PFO, as well as in the Post-procedural assessment after transcatheter closure with a NBO. Methods: We conducted a prospective, single-center clinical study of 44 patients who were diagnosed with PFO by contrast transthoracic echocardiography (c-TTE) and TEE from June 2019 to June 2020. All patients underwent PFO occlusion with NBO under TTE guidance. Follow-up was performed at 2 days and 3 months after the procedure with TTE, and at 6 months and 1 year after the procedure with c-TTE, TTE, and TEE. Results: Interventional treatment was successfully performed in all patients. The left and right sides of the occluder device disc were significantly reduced at 3, 6, and 12 months compared to 2 days after the procedure (all P < 0.01), and decreased gradually. The thickness was significantly reduced at 12 months compared to the first three time points (all P < 0.01). Thrombus was found on the surface of the occluder device in three patients (6.4%) at 3 and 6 months after occlusion. At 6 months after procedure, there were 3 (6.8%) cases of extensive residual right-to-left shunt (RLS), 2 (4.5%) cases of moderate shunt, and 7 (15.9%) cases of small shunts. One year after procedure, 2 (4.5%) cases had a extensive residual shunt, 6 (13.6%) cases of small shunts were confirmed to originate from pulmonary veins by TEE, and the PFO-RLS occlusion rate reached 95.5%. Conclusion: This study demonstrates the feasibility, safety, and effectiveness of NBO for the closure of PFO in humans, with a high rate of complete shunt closure. Accurate TEE assessment of the PFO anatomy before closure with NBO is important to ensure that the procedure remains safe and effective. Furthermore, TEE plays a crucial role in the Post-procedure follow-up.

cardiac & cardiovascular systems
Patent Foramen Ovale and Stroke–Current Status

Oh Young Bang,Mi Ji Lee,Sookyung Ryoo,Suk Jae Kim,Ji Won Kim

DOI: https://doi.org/10.5853/jos.2015.17.3.229

2015-09-30

Journal of Stroke

Abstract:Patent foramen ovale (PFO) is growing in clinical interest because of a renewed focus on embolic stroke of undetermined source (ESUS), the PFO attributable fraction (the 10-point Risk of Paradoxical Embolism score), technical advances in PFO diagnosis, and the emergence of endovascular device closure as a treatment option. However, recent randomized controlled trials of the management of patients with ESUS and PFO failed to demonstrate the superiority of closure over medical treatment. The mechanisms of stroke other than paradoxical embolism may be important in patients with ESUS and PFO. This paper reviews the current understanding of the pathophysiology of stroke and therapeutic options in patients with PFO and ESUS.

peripheral vascular disease,clinical neurology
Numerical Treatment of a Cross-Diffusion Model of Biofilm Exposure to Antimicrobials

K. Rahman,H. Eberl

DOI: https://doi.org/10.1007/978-3-642-55224-3_14

2013-09-08

Abstract:
Insights into Spray Development from Metered-Dose Inhalers Through Quantitative X-ray Radiography

N. Mason-Smith,D. Duke,A. Kastengren,P. Stewart,D. Traini,P. Young,Yang Chen,D. Lewis,J. Soria,D. Edgington-Mitchell,D. Honnery

DOI: https://doi.org/10.1007/s11095-016-1869-5

IF: 4.58

2016-02-17

Pharmaceutical Research

Abstract:
Insights from a 23-Year Monocentric Analysis

Elham Kayvanpour,Elena Matzeit,Ziya Kaya,Sven Pleger,Anke Bahrmann,Christine Reichardt,Peter Arthur Ringleb,Norbert Frey,Benjamin Meder,Farbod Sedaghat-Hamedani

DOI: https://doi.org/10.3390/jcm13216354

IF: 3.9

2024-10-24

Journal of Clinical Medicine

Abstract:Background/Objectives: Patent foramen ovale (PFO) is a congenital heart defect affecting up to 25% of the population, associated with an increased risk of cryptogenic stroke. Percutaneous PFO closure is a minimally invasive procedure aimed at reducing stroke risk by eliminating the right-to-left shunt. Methods: This monocentric, retrospective study analyzed 716 patients who underwent PFO closure between January 2000 and February 2023. Data collected included demographics, indications for closure, procedural details, and outcomes. Key endpoints were complications at the puncture site, pericardial effusion, recurrent stroke or transient ischemic attack (TIA), thrombi on the device, new-onset atrial fibrillation, and death. Results: The cohort had a mean age of 50.6 ± 12.6 years, with 60.8% female. Four devices were used: Occlutech PFO occluder (n = 106), Amplatzer PFO occluder (n = 227), Gore septal occluder (n = 296), and Cardia PFO-Star (n = 87). The initial procedural success rate was 98.9%, with no significant differences between devices. Complication rates were low across all devices. Residual shunt incidence decreased from 17.9% in 1 month to 3.4% in 12 months. Device-specific complications included late-onset pericardial effusion (p = 0.01), erosions (Cardia PFO-Star), and device thrombus formation (Gore septal occluder). Conclusions: PFO closure is a safe and effective method for preventing recurrent strokes, with high success rates and varying specific complication profiles, depending on the device. Further long-term studies are needed to evaluate newer devices and optimize patient outcomes.

medicine, general & internal
Updates on Patent Foramen Ovale (PFO) Closure

Konstantinos V. Voudris,Marie-France Poulin,Clifford J. Kavinsky

DOI: https://doi.org/10.1007/s11886-024-02073-y

IF: 3.955

2024-06-25

Current Cardiology Reports

Abstract:Patent foramen ovale (PFO) has been previously linked to left circulation thromboembolism and stroke. This review article aims to discuss the latest evidence, updated societal guidelines, diagnostic algorithms and novel therapeutic devices for PFO closure.

cardiac & cardiovascular systems
A new era in patent foramen ovale closure - a percutaneous suture-based 'deviceless' technique (NobleStitch®): Experience of a Portuguese center

Ana Neto,Carlos Xavier Resende,Marta Tavares Silva,João Carlos Silva,Filipe Macedo

DOI: https://doi.org/10.1016/j.repc.2021.08.015

Abstract:Introduction: In patients with cryptogenic stroke, one of the most frequently found abnormalities is patent foramen ovale (PFO). Percutaneous 'deviceless' systems based on surgical suture-mediated PFO closure have recently been introduced and show a favorable efficacy and safety profile with clear advantages. Objectives: To present procedural details of the technique and baseline characteristics of patients who underwent the procedure in our center. Methods: A single-center prospective observational registry was established between February 2020 and February 2021, to assess the safety, efficacy and possible advantages of a novel percutaneous PFO closure system (NobleStitch® EL). Patient and PFO characteristics as well as technical features were collected for analysis. Results: Twenty-three patients were considered suitable for this technique after transesophageal echocardiography. Their mean age was 51 years and 69.5% were women. Most patients (91.3%) had a history of cryptogenic stroke. PFO closure with the NobleStitch® system was successfully performed in all patients. All procedures were performed under local anesthesia and fluoroscopic monitoring. The mean duration of the procedure was 52 min and median contrast dose used was 187 ml. Median radiation dose absorbed per patient was 61.5 Gy cm2. All patients were discharged asymptomatic 24 hours after the procedure with no peri- or postprocedural complications recorded. Conclusion: Suture-mediated PFO closure represents a valid and safe alternative to traditional umbrella-like devices, and is feasible in the majority of PFO anatomies. Follow-up information, results of larger series and clinical trials may possibly validate this technique as the first choice for PFO closure.
Value of Intracardiac Echocardiography in the Interventional Closure of Patent Foramen Ovale with Adjacent Atrial Septal Defect

Boqian Zhu,Tao Zhu,Jianing Fan,Xiaochun Zhang

DOI: https://doi.org/10.1155/2024/1859229

2024-05-29

Journal of Interventional Cardiology

Abstract:Objective. This study aimed to investigate the application value of intracardiac echocardiography (ICE) in transcatheter closure of a patent foramen ovale (PFO) combined with an adjacent atrial septal defect (ASD). Methods. This retrospective study included five patients with PFO combined with adjacent ASD who underwent transcatheter closure and were admitted to the Zhongshan Hospital of Fudan University from June to September 2023. General conditions, ultrasound and ICE findings, and operative data were recorded and followed up for 2–6 months. Results. Of the five patients, two and three had embolic stroke of undetermined source and migraine, respectively, aged 45.6 ± 12.0 years. All patients underwent successful transcatheter closure via the PFO tunnel under the guidance of ICE, without complications or new stroke, and showed significantly reduced migraine at the follow‐up. Conclusion. In patients with PFO combined with adjacent ASD, closure of a PFO tunnel could be successfully achieved under ICE guidance; its clinical efficacy was accurate and worthy of promotion.

cardiac & cardiovascular systems
Safety of Same-Day Hospital Discharge Post Patent Foramen Ovale Closure: Findings from a Multicenter Study

David Blusztein,Shabir Sarwary,Devang S Parikh,Santiago Garcia,Matthew J Price,Keshav Nayak,Joseph Aragon,Vaikom S Mahadevan

DOI: https://doi.org/10.1016/j.amjcard.2023.09.045

2023-12-01

Abstract:Transcatheter patent foramen ovale (PFO) closure is indicated for patients with cryptogenic stroke. Although procedural safety is well established, there are limited data on the safety of same-day (SD) discharge. We aimed to review the outcomes of PFO closure with SD. Patients who underwent transcatheter PFO closure between January 2011 and May 2022 at 4 large US hospitals were retrospectively analyzed, comparing outcomes of SD versus delayed discharge (DD). The primary end point was a composite of access-site complication, stroke, device embolization, atrial arrhythmia, and bleeding. Secondary analysis comparing imaging modality and outcomes was performed. 554 patients (49.2% female) were analyzed (382 discharged SD). Average age was 54.3 ± 15. Baseline characteristics in both groups were broadly similar. Previous stroke (78.0% SD vs 76.2% DD, p = 0.32) was the commonest indication for PFO closure. In the SD group, there was less general anesthesia use (5.5% vs 16.9%, p <0.001). Intraprocedural intracardiac echocardiography was used more frequently in SD cases (95.0% vs 81.4%, p <0.001). In the DD group, median stay was 1 night, and 34.9% stayed beyond 1 night. At 30 days, there was no difference in the primary composite end point (14.9% vs 11.6%, p = 0.15). There was no inter-group difference in individual adverse events (all p >0.05). When comparing imaging modality and outcomes, there was no difference in composite end points between transesophageal and intracardiac echocardiography (6.5% vs 14.7%, p = 0.063). In conclusion, SD discharge after transcatheter PFO closure appears safe. This efficient approach may be advantageous in optimizing workflow and minimizing hospital occupancy.

[Intradermal reaction with Paracoccidoides brasiliensis polysaccharide in South American blastomycosis].

A node-disjoint multi-path extension of the location prediction based routing protocol for mobile ad hoc networks

CHILD syndrome in 3 generations: the importance of mild or minimal skin lesions.

Transesophageal echocardiography guidance for percutaneous closure of PFO and a new method to improve the diagnosis and safety during the procedures

Patent Foramen Ovale Closure for Nonstroke Indications

Current status of transcatheter closure of patent foramen ovale

Urinary bladder prostanoids--their synthesis, function and possible role in the pathogenesis and treatment of disease.

Patent Foramen Ovale Closure in Special Clinical Situations: More Questions Than Answers?

Transcatheter PFO closure for cryptogenic stroke: current approaches and future considerations

Transcatheter closure of patent foramen ovale with radiofrequency: Acute and intermediate term results in 144 patients

Clinical efficacy of solo transcatheter closure of patent foramen ovale guided by transthoracic echocar-diography

Comparison of three echo-guidance techniques in percutaneous patent foramen ovale closure for stroke prevention: Conventional transoesophageal, microprobe transoesophageal and intracardiac echocardiography

A Prospective, Single-Center, Phase I Clinical Trial to Evaluate the Value of Transesophageal Echocardiography in the Closure of Patent Foramen Ovale With a Novel Biodegradable Occluder

Patent Foramen Ovale and Stroke–Current Status

Numerical Treatment of a Cross-Diffusion Model of Biofilm Exposure to Antimicrobials

Insights into Spray Development from Metered-Dose Inhalers Through Quantitative X-ray Radiography

Insights from a 23-Year Monocentric Analysis

Updates on Patent Foramen Ovale (PFO) Closure

A new era in patent foramen ovale closure - a percutaneous suture-based 'deviceless' technique (NobleStitch®): Experience of a Portuguese center

Value of Intracardiac Echocardiography in the Interventional Closure of Patent Foramen Ovale with Adjacent Atrial Septal Defect

Safety of Same-Day Hospital Discharge Post Patent Foramen Ovale Closure: Findings from a Multicenter Study